448 related articles for article (PubMed ID: 29180117)
1. The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance.
Yao S; Fan LY; Lam EW
Semin Cancer Biol; 2018 Jun; 50():77-89. PubMed ID: 29180117
[TBL] [Abstract][Full Text] [Related]
2. Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance.
Nestal de Moraes G; Bella L; Zona S; Burton MJ; Lam EW
Curr Drug Targets; 2016; 17(2):164-77. PubMed ID: 25418858
[TBL] [Abstract][Full Text] [Related]
3. Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis.
Saavedra-García P; Nichols K; Mahmud Z; Fan LY; Lam EW
Mol Cell Endocrinol; 2018 Feb; 462(Pt B):82-92. PubMed ID: 28087388
[TBL] [Abstract][Full Text] [Related]
4. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.
Zhao F; Lam EW
Front Med; 2012 Dec; 6(4):376-80. PubMed ID: 23124885
[TBL] [Abstract][Full Text] [Related]
5. FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy.
Wilson MS; Brosens JJ; Schwenen HD; Lam EW
Curr Drug Targets; 2011 Aug; 12(9):1256-66. PubMed ID: 21443467
[TBL] [Abstract][Full Text] [Related]
6. Integrating bioinformatics and experimental models to investigate the mechanism of the chelidonine-induced mitotic catastrophe via the AKT/FOXO3/FOXM1 axis in breast cancer cells.
Li H; Tang X; Sun Z; Qu Z; Zou X
Biomol Biomed; 2024 May; 24(3):560-574. PubMed ID: 37976368
[TBL] [Abstract][Full Text] [Related]
7. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance.
Gomes AR; Zhao F; Lam EW
Chin J Cancer; 2013 Jul; 32(7):365-70. PubMed ID: 23706767
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.
Wierstra I
Adv Cancer Res; 2013; 119():191-419. PubMed ID: 23870513
[TBL] [Abstract][Full Text] [Related]
9. Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis.
Ghosh S; Singh R; Vanwinkle ZM; Guo H; Vemula PK; Goel A; Haribabu B; Jala VR
Theranostics; 2022; 12(12):5574-5595. PubMed ID: 35910798
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
11. Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells.
Alasiri G; Jiramongkol Y; Zona S; Fan LY; Mahmud Z; Gong G; Lee HJ; Lam EW
Oncogene; 2019 Sep; 38(36):6382-6398. PubMed ID: 31312024
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal regulation between GCN2 (eIF2AK4) and PERK (eIF2AK3) through the JNK-FOXO3 axis to modulate cancer drug resistance and clonal survival.
Alasiri G; Jiramongkol Y; Trakansuebkul S; Ke HL; Mahmud Z; Intuyod K; Lam EW
Mol Cell Endocrinol; 2020 Sep; 515():110932. PubMed ID: 32615282
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.
McGovern UB; Francis RE; Peck B; Guest SK; Wang J; Myatt SS; Krol J; Kwok JM; Polychronis A; Coombes RC; Lam EW
Mol Cancer Ther; 2009 Mar; 8(3):582-91. PubMed ID: 19276163
[TBL] [Abstract][Full Text] [Related]
14. Forkhead box M1 (FOXM1) expression predicts disease free survival and may mediate resistance to chemotherapy and hormonotherapy in male breast cancer.
Abdeljaoued S; Bettaieb L; Nasri M; Adouni O; Goucha A; Bouzaiene H; Boussen H; Rahal K; Gamoudi A
Breast Dis; 2018; 37(3):109-114. PubMed ID: 29504520
[TBL] [Abstract][Full Text] [Related]
15. Targeting forkhead box M1 transcription factor in breast cancer.
O'Regan RM; Nahta R
Biochem Pharmacol; 2018 Aug; 154():407-413. PubMed ID: 29859987
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation.
Aimjongjun S; Mahmud Z; Jiramongkol Y; Alasiri G; Yao S; Yagüe E; Janvilisri T; Lam EW
BMC Cancer; 2019 Nov; 19(1):1106. PubMed ID: 31727006
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of FoxM1 by MnSOD Overexpression Contributes to Cancer Stem-Like Cell Characteristics in the Lung Cancer H460 Cell Line.
Fu Z; Cao X; Yang Y; Song Z; Zhang J; Wang Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818789635. PubMed ID: 30111255
[TBL] [Abstract][Full Text] [Related]
18. FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance.
Zona S; Bella L; Burton MJ; Nestal de Moraes G; Lam EW
Biochim Biophys Acta; 2014 Nov; 1839(11):1316-22. PubMed ID: 25287128
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 confers acquired cisplatin resistance in breast cancer cells.
Kwok JM; Peck B; Monteiro LJ; Schwenen HD; Millour J; Coombes RC; Myatt SS; Lam EW
Mol Cancer Res; 2010 Jan; 8(1):24-34. PubMed ID: 20068070
[TBL] [Abstract][Full Text] [Related]
20. Promyelocytic leukemia protein (PML) controls breast cancer cell proliferation by modulating Forkhead transcription factors.
Sachini N; Arampatzi P; Klonizakis A; Nikolaou C; Makatounakis T; Lam EW; Kretsovali A; Papamatheakis J
Mol Oncol; 2019 Jun; 13(6):1369-1387. PubMed ID: 30927552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
